Quidelortho Corp
F:QL1A
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.9
43.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Quidelortho Corp
F:QL1A
|
1.9B EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
191.1B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
190.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.6B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
137.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
130.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
49.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
56.2B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49.6B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
38B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Quidelortho Corp
Glance View
QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream. The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Quidelortho Corp is -50.8%, which is below its 3-year median of -29.1%.
Over the last 3 years, Quidelortho Corp’s Net Margin has decreased from 26.1% to -50.8%. During this period, it reached a low of -76.9% on Dec 29, 2024 and a high of 26.1% on Sep 2, 2022.